MHRA (UK)Original article
Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
RegulatoryDomperidoneNegative
AI Analysis
Summary
MHRA has updated product information for all domperidone products to add a contraindication in patients with confirmed or suspected phaeochromocytoma due to risk of severe hypertension.
Outcome Details
New contraindication added for patients with confirmed or suspected phaeochromocytoma due to risk of severe hypertension
Importance:3/10
Sentiment:
-0.30
safety updatecontraindicationMHRAregulatoryphaeochromocytoma
Read the original article
Published by MHRA (UK) on July 21, 2026 1:00 PM